Short-Lived Engineered Bacteria for Therapeutic Action Without Pathogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bacteria used for medical purposes face challenges in ensuring safety and efficacy, particularly in treating diseases like cancers, due to concerns about their ability to grow uncontrollably and cause pathogenesis.
Innovation Solution
Genetically engineered live bacteria with a short lifespan and virulence factors are developed, allowing them to survive long enough to exert medical effects and then die, minimizing pathogenesis. These bacteria are derived from virulent strains and include effector genes that elicit immune responses or therapeutic factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacteria are used for medical purposes (vaccines or drugs), then efficacy in treating diseases is improved, but safety is worsened due to uncontrolled growth and pathogenesis
Solution Approach 1:
The patent applies this principle by creating bacteria with a predetermined short lifespan that die after exerting their medical effect. The bacteria are engineered to survive only long enough to deliver therapeutic cargo (antigens or therapeutic factors) and then undergo programmed cell death, preventing persistent colonization and pathogenesis while maintaining initial medical efficacy.
Solution Approach 2:
The patent applies this principle by making the bacterial lifespan dynamic and controllable rather than fixed or indefinite. Through genetic engineering, the bacteria's life cycle is regulated to transition from a functional state (surviving and expressing effectors) to a terminal state (cell death), allowing the system to adapt its duration based on therapeutic needs while preventing harmful persistence.
2Duration of action of moving object
If bacteria are genetically modified to survive longer, then medical action duration is improved, but pathogenesis risk is worsened
Solution Approach 1:
The patent resolves this contradiction by implementing a short lifespan for the bacteria. They are engineered to die after a predetermined period, which limits the window for potential pathogenesis while still providing sufficient time for medical action to occur. This creates a controlled temporal window where benefit is achieved without long-term risk.
Solution Approach 2:
The patent applies this principle by pre-determining the bacterial lifespan through genetic engineering before administration. The bacteria are designed with built-in temporal limits on their survival, so the duration of medical action is predetermined to be sufficient for therapy but limited enough to prevent pathogenesis, eliminating the need for post-hoc control mechanisms.
3Reliability
If virulent strains are used, then therapeutic effectiveness is improved, but safety is worsened due to inherent pathogenicity
Solution Approach 1:
The patent applies this principle by using virulent strains that are engineered to die after a short period. The inherent pathogenicity of the virulent strain is temporarily harnessed for therapeutic effect (e.g., strong immune stimulation or direct cytotoxicity) but is neutralized by the programmed short lifespan, preventing the bacteria from establishing persistent infection or causing disease.
Solution Approach 2:
The patent applies this principle by dynamically controlling the expression of virulence factors over time. The bacteria are engineered to express pathogenic effects only during a limited window when they are still viable, after which they die and the harmful effects cease. This temporal regulation allows the virulent strain to provide strong initial therapy without causing sustained harm.
Data Source
AI summary
A genetically engineered live bacterium comprising at least one effector gene that encodes a medical effector and at least one gene modification that shortens the bacterium's lifespan. After being administered to a subject, the bacterium survives within a time sufficient to allow the medical effector to exert at least one medical action and dies within a time sufficient to minimize pathogenesis to the subject. The bacterium provides an effective treatment of diseases or improving conditions while ensuring the biosafety for medical use.